Pharvaris N.V.
Pharvaris N.V.（PHVS）内幕交易
基于 SEC Form 4 的买入/卖出笔数、买卖比与情绪标签；可在本季度与近12个月之间切换；下方为季度图与交易明细。
SEC EDGAR · FMP · PHVS · 截至 2026年6月9日
活动摘要
买入笔数
0
P-Purchase only
卖出笔数
34
近12个月
买卖比
0.00
Buy/Sell (by trades)
整体情绪
Pharvaris N.V.内部人在过去近12个月主要在卖出股份，卖出行为通常由预设的Rule 10b5-1计划驱动，不一定代表对公司的负面看法。
▸ 数据来源：SEC EDGAR · Form 3 & 4 · 买入仅计P-Purchase · 卖出仅计S-Sale
截至 2026年6月9日
PHVS 季度内部人买卖趋势
PHVS 内幕交易卖出 · PHVS 内幕交易买入 · 季度活动
Mobile shows last 4Q · Desktop shows full 8Q
▸ 数据来源：SEC EDGAR · Form 3 & 4 · 最近8季度
As of Jun 9, 2026
活跃内部人
近12个月交易最活跃 · PHVS CEO内幕交易
显示全部内部人 · 点击卡片过滤下方交易表
▸ 按reportingName聚合 · 近12月交易次数Top5 · 无额外API
近期内幕交易记录
PHVS 高管卖出股份 · PHVS 董事内幕交易 · SEC Form 4申报
横向滑动查看全部列
| 日期 | 内部人 | 类型 | 股数 | 总金额 | 申报 |
|---|---|---|---|---|---|
| Jun 4, 2026 | Nijdam Anna PAO | Sale | 2,670 | $82K | Form 4 |
| May 21, 2026 | Monges Viviane Director | Sale | 9,667 | $293K | Form 4 |
| May 22, 2026 | Nijdam Anna PAO | Option | 5,501 | $110K | Form 4 |
| May 21, 2026 | Nijdam Anna PAO | Option | 1,829 | $37K | Form 4 |
| May 21, 2026 | Nijdam Anna PAO | Sale | 1,829 | $56K | Form 4 |
| May 22, 2026 | Nijdam Anna PAO | Sale | 5,501 | $169K | Form 4 |
| May 21, 2026 | Nassif David W. CFO / CLO | Sale | 10,000 | $303K | Form 4 |
| May 20, 2026 | Bjork Elisabeth Director | Option | 10,000 | $81K | Form 4 |
| May 20, 2026 | Bjork Elisabeth Director | Sale | 10,000 | $293K | Form 4 |
| May 18, 2026 | Modig Berndt CEO · Director | Sale | 2,292 | $67K | Form 4 |
| May 15, 2026 | Glassman Robert Director | Option | 5,333 | $119K | Form 4 |
| May 15, 2026 | Glassman Robert Director | Sale | 5,333 | $159K | Form 4 |
| May 15, 2026 | Glassman Robert Director | Sale | 4,667 | $139K | Form 4 |
| May 15, 2026 | Abele Stefan Andreas Chief Technical Ops Officer | Sale | 8,748 | $261K | Form 4 |
| May 15, 2026 | Souverijns Wim Chief Commercial Officer | Sale | 10,000 | $299K | Form 4 |
| May 11, 2026 | Lu Peng Chief Medical Officer | Other | 109 | $3K | Form 4 |
| May 12, 2026 | Lu Peng Chief Medical Officer | Other | 117 | $4K | Form 4 |
| May 1, 2026 | Lu Peng Chief Medical Officer | Option | 14,166 | $37K | Form 4 |
| May 1, 2026 | Lu Peng Chief Medical Officer | Sale | 14,023 | $423K | Form 4 |
| May 1, 2026 | Lu Peng Chief Medical Officer | Sale | 143 | $4K | Form 4 |
| Apr 29, 2026 | Schikan Johannes Gerardus Christiaan Petrus Director | Sale | 3,830 | $115K | Form 4 |
| Apr 30, 2026 | Schikan Johannes Gerardus Christiaan Petrus Director | Sale | 28,400 | $861K | Form 4 |
| Apr 30, 2026 | Schikan Johannes Gerardus Christiaan Petrus Director | Sale | 670 | $21K | Form 4 |
| Apr 29, 2026 | Lesage Anne Chief Early Development | Sale | 3,700 | $111K | Form 4 |
| Apr 30, 2026 | Lesage Anne Chief Early Development | Sale | 19,200 | $581K | Form 4 |
Abele Stefan Andreas
Chief Technical Ops Officer
日期
May 15
股数
8,748
均价
$29.82
总金额
$261K
Schikan Johannes Gerardus Christiaan Petrus
Director
日期
Apr 29
股数
3,830
均价
$30.07
总金额
$115K
Schikan Johannes Gerardus Christiaan Petrus
Director
日期
Apr 30
股数
28,400
均价
$30.30
总金额
$861K
Schikan Johannes Gerardus Christiaan Petrus
Director
日期
Apr 30
股数
670
均价
$31.03
总金额
$21K
⚡ = 金额≥$100万 · Award/Option价格显示— · 仅Form4 · 仅普通股
▸ 数据来源：SEC EDGAR · Form 4 申报 · ⚡ = 金额≥$100万 · Award/Option 价格显示 —
关于 PHVS 内幕交易
PHVS 内幕交易
Pharvaris N.V.（PHVS）内幕交易数据来源于公司内部人（包括Lu Peng (Chief Medical Officer), Lesage Anne (Chief Early Development), Nijdam Anna (PAO)）提交的SEC Form 4申报文件。过去12个月内，5位内部人向SEC提交了交易申报。PHVS内部人近期主要在卖出，这可能反映预设的10b5-1计划执行，而非方向性判断。
如需查看Pharvaris N.V.机构持仓比例和内部人持股百分比，请访问持仓（Ownership）标签页 → Ownership tab →
常见问题
PHVS 内幕交易 · 5个问题Pharvaris N.V.（PHVS）的内部人包括高管和董事，如Lu Peng (Chief Medical Officer), Lesage Anne (Chief Early Development), Nijdam Anna (PAO)等。过去12个月内，5位内部人向SEC提交了Form 4交易申报。内部人须在交易日期后2个工作日内完成申报。
▸ 数据来源：FMP /stable/insider-trading/search · SEC EDGAR Form 3 & 4 · RSU归属不计入情绪 · As of Jun 9, 2026